Treating the patient with kidney failure to reduce cardiovascular disease risk

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 4, 2004, Pages 257-268

  Menon, Vandana ^b   Sarnak, Mark ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM ACETATE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM PHOSPHATE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRON; LISINOPRIL; LITHIUM; LOSARTAN; NICARDIPINE; NIFEDIPINE; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PYRROLE DERIVATIVE; RIFAMPICIN; TRIMETHOPRIM; UNINDEXED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTHRALGIA; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD PRESSURE REGULATION; BLOOD VOLUME; BONE DISEASE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY SURGERY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; COUGHING; DIET THERAPY; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE SYSTEM ULCER; DIZZINESS; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; ERYTHROPOIESIS; FATIGUE; FLUSHING; HEADACHE; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEARTBURN; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOTENSION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIFESTYLE; LIVER DYSFUNCTION; METABOLIC ACIDOSIS; MUSCLE INJURY; MYALGIA; NAUSEA; NEUTROPENIA; PARATHYROID HORMONE BLOOD LEVEL; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; RISK REDUCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SURVIVAL; URTICARIA; VASCULAR ACCESS; VOMITING;

EID: 4344679114     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0028-1     Document Type: Review

References (49)

1. The National Institutes of Health: 1998 Annual Data Report. United Stales Renal Data System. Bethesda, MD: The National Institutes of Health, The National Institute of Diabetes and Digestive and Kidney Disease, Division ot Kidney, Urologic, and Hematologic Diseases; 1998.
2. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 suppl 1):S1-S266.
3. Foley RN, Parfrey PS, Sarnak MI: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998, 32:S112-S119.
4. Sarnak MJ, Levey AS, Schoolwerth AC, et al.: Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003, 108:2154-2169.
5. Foley RN, Parfrey PS, Harnett JD, et al.: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995, 47:186-192.
6. Coresh J, Longenecker JC, Miller ER 3rd, et al.: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998, 9:S24-S30.
7. Cheung AK, Sarnak MJ, Yan G, et al.: Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000, 58:353-362.
8. Sarnak MJ: Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003, 45(5 suppl):11-17.
9. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002, 62:1524-1538.
10. Sarnak MJ, Coronado BF, Greene T, et al.: Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002, 57:327-335).
11. Gulleton BF, Hemmelgarn BR: Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial 2003, 16:95-100.
12. http://www.drugstore.com. Accessed January 30, 2004.
13. National Kidney Foundation: K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. Am J Kidney Dis 2003, 41:S1-S92.
14. Zager PG, Nikolic J, Brown RH, et al.: "U" curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc. Kidney Int 1998, 54:561-569.
15. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Special report from the National Kidney Foundation Task Force on Cardiovascular Disease [no authors listed]. Am J Kid Dis 1998, 32:S1-S199.
16. Ffrati S, Zaidenstein R, Dishy V, et al.: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002, 40:1023-1029).
17. Pfeffer MA, McMurray JJ, Velazquez EJ, et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
18. Yusuf S, Sleight P, Pogue J, et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342:145-151.
19. Flather MD, Yusuf S, Kober L, et al.: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000, 355:1575-1581.
20. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 2003, 42:201-208.
21. Mann JE, Gerstein HC, Pogue J, et al.: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001, 134:629-636.
22. Dahlof B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
23. Sica DA, Gehr TW, Fernandez A: Risk-benetit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease. Drug Saf 2000, 22:350-360.
24. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289:2560-2572.
25. Black HR, Elliott WJ, Grandits G, et al.: Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End points (CONVINCE) trial. JAMA 2003, 289:2073-2082.
26. Kestenbaum B, Gillen DL, Sherrard DJ, et al.: Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int 2002, 61:2157-2164.
27. Raggi P, Boulay A, Chasan-Taber S, et al.: Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002, 39:695-701.
28. London GM: Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol 2003, 14:S305-309.
29. National Kidney Foundation: K/DOQ1 Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease [no authors listed]. Am J Kidney Dis 2003, 42:S1-S202.
30. Pereira AA, Sarnak MJ: Anemia as a risk factor for cardiovascular disease. Kidney Int Suppl 2003:S32-S39.
31. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000 [no authors listed]. Am J Kidney Dis 2001, 37(1 suppl 1):S182-S238.
32. Wright RS, Reeder GS, Herzog CA, et al.: Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med 2002, 137:563-570.
33. Shlipak MG, Heidenreich PA, Noguchi H, et al.: Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002, 137:555-562.
34. Cice G, Ferrara L, D'Andrea A, et al.: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003, 41:1438-1444.
35. Herzog CA, Ma JZ, Collins AJ: Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998, 339:799-805.
36. Herzog CA: Poor long-term survival of dialysis patients after acute myocardial infarction: bad treatment or bad disease? Am J Kidney Dis 2000, 35:1217-1220.
37. Herzog CA, Ma JZ, Collins AJ: Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002, 106:2207-2211.
38. Szczech LA, Reddan DN, Owen WF et al.: Differential survival after coronary revascularization procedures among patients with renal insufficiency. Kidney Int 2001, 60:292-299.
39. Hall RE, Ash AS, Ghali WA, Moskowitz MA: Hospital cost of complications associated with coronary artery bypass graft surgery. Am J Cardiol 1997, 79:1680-1682.
40. Favarato D, Hueb W, Gersh BJ, et al.: Relative cost comparison of treatments for coronary artery disease: the first year follow-up of MASS II Study. Circulation 2003, 108(suppl 1):1121-1123.
41. Hase H, Nakamura M, Joki N, et al.: Independent predictors of restenosis after percutaneous coronary revascularization in haemodialysis patients. Nephrol Dial Transplant 2001, 16:2372-2377.
42. Yock CA, Boothroyd DB, Owens DK, et al.: Cost-effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. Am J Mol 2003, 115:382-389.
43. Tepel M, van der Giet M, Statz M, et al.: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulalion 2003, 107:992-995.
44. Boaz M, Smetana S, Weinstein T, et al.: Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000, 356:1213-1218.
45. Clarke R, Lewington S, Landray M: Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int Suppl 2003, (84):S131-S133.
46. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
47. Arici M, Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-ractive protein the missing link? Kidney Int 2001, 59:407-414.
48. Schieffer B, Drexler H: Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases. Am J Cardiol 2003, 91:12H-18H.
49. Eknoyan G, Beck GJ, Cheung AK, et al.: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002, 347:2010-2019.